SBRT2015

Previous Page

Next Page

Page Background

106 patients

spinal (

n

=55)

cerebral (

n

=51) metastatic lesions

E C O G: 0 or 1

sorafenib or sunitinib

simultaneous SRS.

Primary : local control.

Secondary : toxicity and overall survival.